Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isoniazid Inhalation in Patients With Tuberculosis
NCT07708779Phase 1Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Dec 2025
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of isoniazid in Tuberculosis (TB), sponsored by University Medical Center Groningen. Primary endpoint: Local tolerability of the inhalation of INH at 25 hours. Started Dec 2025; status: recruiting.
02
Drugs
isoniazid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT07708779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07708779.